Over 300 Total Lots Up For Auction at Two Locations - UT 10/25, CA 10/28

Biotech company in China selects Medidata Technology Platform to help with clinical oncology trial

por Lauren Dubinsky, Senior Reporter | March 24, 2016
Follow us on Twitter: @Medidata
Find us on LinkedIn
About Shanghai Henlius Biotechnology

Shanghai Henlius Biotech Co., Ltd. is a joint venture company formed by Shanghai Fosun Pharmaceutical Co., Ltd. and Henlius Biopharmaceuticals Co., Ltd. in December 2009. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters and novel mAbs using cutting-edge technology. Registered in Shanghai Zhangjiang, the company has so far invested over 400 million RMB in the early development of monoclonal antibody drugs.

Products currently in development cover a variety of therapeutic areas including oncology and autoimmune diseases. Henlius' R&D management team has extensive experience in the development and commercialization of a range of monoclonal antibody drugs in such leading international pharmaceutical and biotech companies as Genentech, Amgen, BMS, Eli Lilly and Chiron. The concept of Henlius' drug development lies in global integrative innovation, and the company has a total of 3 R&D laboratories located in China (Shanghai), the US (California) and Taiwan (Taipei).

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Contacts
Investor:
Medidata Solutions
Hulus Alpay, +1 212-419-1025
halpay@mdsol.com
or
Media:
Medidata Solutions
Nicole Pariser, +1 212-659-1069
npariser@mdsol.com
or
Media-APAC:
Medidata Solutions
Da Jeong Chong, +82 2-2015-7715
dchong@mdsol.com

Back to HCB News

You Must Be Logged In To Post A Comment